PolyNovo (ASX:PNV) has announced it has progressed its specialised skin cell research project, which produces insulin under the skin for people with type I diabetes.
The medical innovation company, in collaboration with Beta Cell Technologies, received successful results from the trial of NovoSorb BTM in pigs.
In the trial, islet cells from the pancreas were implanted into NovoSorb BTMs which help to produce human insulin and reduce rejection.
PolyNovo says it’s exciting proof and potentially an early step in creating a ‘dermal depot’ in the skin, which potentially removes the need for insulin injections in type 1 diabetes sufferers.
Shares in PolyNovo (ASX:PNV) opened 4.55% higher to 23 cents.